Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Virax Biolabs Group Limited (VRAX)

Virax Biolabs Group Limited (VRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,329
  • Shares Outstanding, K 4,342
  • Annual Sales, $ 10 K
  • Annual Income, $ -6,060 K
  • EBIT $ 0 M
  • EBITDA $ -6 M
  • 60-Month Beta 1.69
  • Price/Sales 227.23
  • Price/Cash Flow N/A
  • Price/Book 0.27
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 10/01/25
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3032 +0.92%
on 01/13/26
0.5089 -39.87%
on 12/31/25
-0.0920 (-23.12%)
since 12/16/25
3-Month
0.3032 +0.92%
on 01/13/26
0.8700 -64.83%
on 12/03/25
-0.3091 (-50.25%)
since 10/16/25
52-Week
0.3032 +0.92%
on 01/13/26
2.3300 -86.87%
on 01/22/25
-1.8340 (-85.70%)
since 01/16/25

Most Recent Stories

More News
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

LONDON , Dec. 4, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research...

VRAX : 0.3060 (-2.55%)
Virax Biolabs Group Limited Announces $5 Million Private Placement

LONDON , Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research...

VRAX : 0.3060 (-2.55%)
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

Virax Biolabs' proprietary in-development diagnostic technology for post-acute infection syndromes ("PAIS"), such as Long COVID, positions the Company for an important data year ahead, following a series...

VRAX : 0.3060 (-2.55%)
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmuneâ„¢ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

LONDON , Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and...

VRAX : 0.3060 (-2.55%)
Virax Biolabs Partners with Emory University on ViraxImmuneâ„¢ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

LONDON , Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune response detection...

VRAX : 0.3060 (-2.55%)
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

LONDON , July 29, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses...

VRAX : 0.3060 (-2.55%)
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

LONDON , July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses...

VRAX : 0.3060 (-2.55%)
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar

/PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune...

VRAX : 0.3060 (-2.55%)
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum

/PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune...

VRAX : 0.3060 (-2.55%)
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid

/PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune...

VRAX : 0.3060 (-2.55%)

Business Summary

Virax Biolabs Group Limited is a biotechnology company focused on the prevention, detection, and diagnosis of viral diseases as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. Virax Biolabs Group Limited is based in London, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 0.3458
2nd Resistance Point 0.3379
1st Resistance Point 0.3219
Last Price 0.3060
1st Support Level 0.2980
2nd Support Level 0.2901
3rd Support Level 0.2741

See More

52-Week High 2.3300
Fibonacci 61.8% 1.5558
Fibonacci 50% 1.3166
Fibonacci 38.2% 1.0774
Last Price 0.3060
52-Week Low 0.3032

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar